Trial Profile
A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms COLET
- Sponsors Roche
- 16 Mar 2023 Status changed from completed to discontinued.
- 30 Oct 2022 Results of pooled analysis form NCT03178851, NCT01689519, NCT02322814, and NCT02788279 of safety analysis, published in the Drug Safety
- 10 Nov 2021 Status changed from active, no longer recruiting to completed.